November 7, 2016
Orphan drugs make 35% Horizon's sale in Q3 2016
Horizon Pharma has announced its third-quarter 2016 financial results on Monday.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Ravicti
November 3, 2016
Horizon’s urea cycle disorder drug to sell in Canada
Horizon Pharma has announced that Ravicti (glycerol phenylbutyrate) Oral Liquid is now available in Canada through its affiliate….
November 30, 2015
European Commission approves Horizon’s Ravicti for treating Urea Cycle Disorders
Horizon Pharma and its affiliate, Horizon Therapeutics, has gotten the European Commission’s (EC’s) approval for Ravicti – glycerol phenylbutyrate – Oral Liquid for use as an adjunctive therapy for chronic management patients with six subtypes of Urea Cycle Disorders (UCDs).